Payment overview · 2025
General Payments
$163.95
6 reported records · 6 companies
Healthcare provider profile · identity verified
David Jansma, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BEAVER, PA · NPI 1013974633
Verified facts
What the public records show
CMS Open Payments records show David Jansma, M.D. received $163.95 in general payments during 2025 across 6 reported records.
Baxter Healthcare accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nurtec Odt, Ozempic, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Baxter Healthcare | Unresolved — no canonical attribution shown | $60.77 | 37.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.00 | 15.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.88 | 15.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.87 | 13.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.74 | 9.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.69 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.18 | 5 |
| Debt forgiveness | $60.77 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 701 | 160 |
| Omeprazole | Omeprazole | 565 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 564 | 131 |
| Lisinopril | Lisinopril | 558 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 374 | 94 |
| Gabapentin | Gabapentin | 315 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 275 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 57 |
| Potassium Chloride | Potassium Chloride | 248 | 59 |
| Metformin Hcl | Metformin Hcl | 235 | 55 |
| Losartan Potassium | Losartan Potassium | 234 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 50 |
| Furosemide | Furosemide | 217 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 41 |
| Simvastatin | Simvastatin | 201 | 42 |
| Carvedilol | Carvedilol | 199 | 46 |
| Eliquis | Apixaban | 181 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 38 |
| Allopurinol | Allopurinol | 166 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 47 |
| Lorazepam | Lorazepam | 150 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 53 |
| Sertraline Hcl | Sertraline Hcl | 149 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 31 |
| Meloxicam | Meloxicam | 133 | 27 |
| Mirtazapine | Mirtazapine | 132 | 22 |
| Bupropion Xl | Bupropion Hcl | 129 | 22 |
| Prednisone | Prednisone | 128 | 89 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 24 |
| Famotidine | Famotidine | 126 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 39 |
| Alendronate Sodium | Alendronate Sodium | 121 | 23 |
| Montelukast Sodium | Montelukast Sodium | 118 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 26 |
| Tramadol Hcl | Tramadol Hcl | 110 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 23 |
| Donepezil Hcl | Donepezil Hcl | 107 | 24 |
| Trazodone Hcl | Trazodone Hcl | 107 | 25 |
| Metformin Hcl Er | Metformin Hcl | 105 | 28 |
| Buspirone Hcl | Buspirone Hcl | 101 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 25 |
| Jardiance | Empagliflozin | 90 | 17 |
| Glimepiride | Glimepiride | 89 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 17 |
| Atenolol | Atenolol | 83 | 19 |
| Xarelto | Rivaroxaban | 83 | 15 |
| Irbesartan | Irbesartan | 81 | 23 |
| Alprazolam | Alprazolam | 80 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 20 |
| Glipizide | Glipizide | 77 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 15 |
| Aripiprazole | Aripiprazole | 73 | suppressed |
| Synthroid | Levothyroxine Sodium | 71 | 15 |
| Valsartan | Valsartan | 68 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 17 |
| Celecoxib | Celecoxib | 67 | 26 |
| Amoxicillin | Amoxicillin | 66 | 55 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 16 |
| Ezetimibe | Ezetimibe | 62 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 20 |
| Ozempic | Semaglutide | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | 11 |
| Doxepin Hcl | Doxepin Hcl | 48 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 13 |
| Verapamil Er | Verapamil Hcl | 45 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 11 |
| Valacyclovir | Valacyclovir Hcl | 42 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Ondansetron Odt | Ondansetron | 41 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 31 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Nystatin | Nystatin | 38 | 19 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 11 |
| Finasteride | Finasteride | 35 | 11 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 18 |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Farxiga | Dapagliflozin Propanediol | 29 | 11 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Indapamide | Indapamide | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 25 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 22 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $163.95 · 6 records | Baxter Healthcare | FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, VOQUEZNA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error